Clinical Trial

ctDNA in HER2+ EBC Neoadjuvant Treatment

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-04.
Trial Details
NCT Number NCT07335081
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Breast Cancer
Enrollment 60 participants
Start Date 2024-02-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24